Prescribing overview
This dosing summary covers single-ingredient Bravecto canine chews only. Topical, Plus, 1-Month and Quantum presentations require their separate labels.
Key prescribing checks
- Review seizure or neurologic history. Isoxazolines have been associated with tremors, incoordination and seizures, including reports in dogs without prior seizures.
- Confirm species, age, weight, route and target tick species. Protection duration differs for some ticks; do not turn a marketing duration into a universal coverage claim.
- Topical products must not be administered orally. The feline topical label has not established safety in breeding, pregnant or lactating cats. Review adverse events and current labeling when choosing repeat treatment.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
FDA-approved Bravecto chew indicationsFleas and specified ticks
12-week claims: C. felis, I. scapularis, D. variabilis, R. sanguineus, H. longicornis; A. americanum: 8 weeks.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Antagonizes arthropod GABA- and glutamate-gated chloride channels.
Absorption, distribution, metabolism and elimination
Dogs receiving oral chews: peaks 2 hours–3 days; elimination half-life 9.3–16.2 days. Fasting reduces bioavailability.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Bravecto
U.S. veterinary label. Dogs: oral chews.
Contraindications · when not to use
- The label explicitly reports no known contraindications.
Precautions & monitoring
- Use cautiously with neurologic history; isoxazolines can cause tremor, incoordination or seizures.
- Review adverse reports in breeding females.
Bravecto Topical Solution for Dogs
U.S. veterinary label. Dogs: topical solution.
Contraindications · when not to use
- The label explicitly reports no known contraindications.
Precautions & monitoring
- Use cautiously with neurologic history; isoxazolines can cause tremor, incoordination or seizures.
- Avoid oral ingestion; review reproductive safety information and breeding-female adverse reports.
Bravecto Topical Solution for Cats
U.S. veterinary label. Cats: topical solution.
Contraindications · when not to use
- The label explicitly reports no known contraindications.
Precautions & monitoring
- Use cautiously with neurologic history; isoxazolines can cause tremor, incoordination or seizures.
- Breeding, pregnancy and lactation safety is unestablished; avoid oral ingestion.
These summaries exclude Bravecto Plus, 1-Month and Quantum, which have separate labels.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Vomiting, diarrhea and lethargy; isoxazolines can cause tremors, ataxia or seizures.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
| Species & indication | Labeled regimen | Eligibility & source |
|---|---|---|
| Dogs ≥6 months, ≥4.4 lbLabeled fleas/ticksBravecto chews | Minimum 25 mg/kg (11.4 mg/lb), using label weight-band chew Oral with food · Every 12 weeks; may administer every 8 weeks for A. americanum exposure May continue year-round | Above 123 lb use appropriate chew combination. Verify full dosing label ↗ |
Do not generalize this interval to other Bravecto products.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
A product-specific interaction summary has not been established here. An empty list must not be interpreted as “no interactions.” Review the full source and a species-appropriate clinical reference.
Monitoring
Review neurologic history and new neurologic signs.
Client counseling
Confirm complete ingestion; keep chews inaccessible to animals.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Do not exceed 30°C; retain original packaging until use.
Brands, formulations & ingredient identity
Active ingredients
Fluralaner
Bravecto Chews and Bravecto Topical Solution contain fluralaner but have distinct administration instructions. The dog topical and cat topical products are separate presentations.
Bravecto Plus contains fluralaner with moxidectin and is not a single-ingredient synonym. Bravecto 1-Month and Bravecto Quantum also require their own product-specific directions; the name Bravecto alone is insufficient for dispensing.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Bravecto
- Formulation
- Oral chews for dogs
- Label / product scope
- Dogs
Single-ingredient fluralaner chew; exact product suffix and label matter.
Product label / source ↗Bravecto Topical Solution for Dogs
- Formulation
- Topical solution
- Label / product scope
- Dogs
Canine topical presentation.
Product label / source ↗Bravecto Topical Solution for Cats
- Formulation
- Topical solution
- Label / product scope
- Cats
Feline topical presentation; distinct from Bravecto Plus.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.